GOLDENWELL BIOTECH, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
GOLDENWELL BIOTECH, INC. (GWLL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$15.63 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$13.36K.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-06-30 was $59.38K, a 3861.31% increase year-over-year.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$32.28K.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-06-30 was $1.50K.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$22.63K.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$3.83K, a 152.90% decline from fiscal 2023.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $7.24K.
- GOLDENWELL BIOTECH, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$167.56K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$15.63K 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | -$13.36K 10-Q · filed 2026-07-01 | |||||
| 2025-12-31 | -$22.63K 10-K · filed 2026-07-01 | |||||
| 2025-09-30 | -$3.78K 10-Q/A · filed 2026-06-29 | |||||
| 2025-06-30 | $59.38K 10-Q · filed 2025-09-12 | $27.10K 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | -$32.28K 10-Q · filed 2026-07-01 | -$32.28K 10-Q · filed 2025-05-27 | ||||
| 2024-12-31 | -$3.83K 10-K · filed 2026-07-01 | |||||
| 2024-09-30 | -$48.48K 10-Q/A · filed 2026-06-29 | |||||
| 2024-06-30 | $1.50K 10-Q · filed 2025-09-12 | -$27.51K 10-Q/A · filed 2026-06-26 | ||||
| 2024-03-31 | -$29.01K 10-Q/A · filed 2026-06-26 | |||||
| 2023-12-31 | $7.24K 10-K · filed 2025-05-15 | |||||
| 2023-09-30 | -$5.21K 10-Q · filed 2023-11-13 | -$34.08K 10-Q · filed 2023-11-13 | -$34.08K 10-Q · filed 2024-11-26 | |||
| 2023-06-30 | -$26.95K 10-Q · filed 2024-08-22 | -$28.87K 10-Q · filed 2024-08-22 | ||||
| 2023-03-31 | -$1.92K 10-Q · filed 2024-05-20 | |||||
| 2022-12-31 | -$167.56K 10-K · filed 2024-04-12 | |||||
| 2022-09-30 | $15.22K 10-Q · filed 2023-11-13 | -$155.47K 10-Q · filed 2023-11-13 | -$155.47K 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$25.04K 10-Q · filed 2023-08-17 | -$170.69K 10-Q · filed 2023-08-17 | ||||
| 2022-03-31 | -$145.66K 10-Q · filed 2023-05-19 | -$145.65K 10-Q · filed 2022-05-18 | ||||
| 2021-12-31 | -$35.01K 10-K · filed 2023-04-13 | -$35.01K 10-K/A · filed 2023-02-06 | ||||
| 2021-09-30 | -$12.51K 10-Q · filed 2022-11-14 | -$15.64K 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $19.92K 10-Q · filed 2022-08-15 | -$3.13K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $19.93K 10-Q · filed 2022-05-18 | |||||
| 2020-12-31 | $1.98K 10-K/A · filed 2023-02-06 |